Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Acquired by a larger pharmaceutical company in 2021
|
| gptkbp:can_lead_to |
gptkb:TTI-621
gptkb:TTI-622 |
| gptkbp:ceo |
gptkb:Dr._S._S._K._Tan
|
| gptkbp:clinical_trial |
gptkb:Asia
Phase 2 hundreds of patients ongoing trials adaptive trial designs overall survival and response rate promising results in early trials T cell therapy for cancer collecting extensive clinical data funded by venture capital and grants monitoring clinical trial outcomes closely multiple phases of clinical trials |
| gptkbp:collaborations |
with various research institutions
with international research teams collaborating with universities and hospitals |
| gptkbp:community_engagement |
active in patient advocacy groups
|
| gptkbp:developer |
investing in new technologies for treatment
|
| gptkbp:develops |
T cell therapies
|
| gptkbp:employees |
over 100
|
| gptkbp:focuses_on |
gptkb:drug
|
| gptkbp:founded |
gptkb:2012
|
| gptkbp:founder |
gptkb:Dr._S._S._K._Tan
|
| gptkbp:future_plans |
expand clinical trials globally
planning future research initiatives. |
| gptkbp:global_presence |
expanding presence in global markets
|
| gptkbp:headquarters |
gptkb:Singapore
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tessa Therapeutics
|
| gptkbp:industry |
operates in the biotechnology sector
|
| gptkbp:innovation |
focused on innovative cancer therapies
|
| gptkbp:invention |
multiple patents in cell therapy
|
| gptkbp:investment |
gptkb:Sequoia_Capital
Asia-Pacific region raised over $100 million in funding |
| gptkbp:license |
plans to submit for FDA approval
|
| gptkbp:marketing_strategy |
targeting unmet medical needs in oncology
|
| gptkbp:mission |
to develop innovative therapies for cancer
|
| gptkbp:partnership |
gptkb:National_University_of_Singapore
with pharmaceutical companies |
| gptkbp:partnerships |
with leading cancer research centers
|
| gptkbp:platform |
proprietary technology for T cell engineering
|
| gptkbp:population |
diverse patient demographics
|
| gptkbp:publishes |
published research in peer-reviewed journals
|
| gptkbp:receives_funding_from |
grants from government and private sectors
|
| gptkbp:recruitment |
strategies for recruiting diverse patients
|
| gptkbp:regulatory_compliance |
complies with international regulations
FDA approval for trials |
| gptkbp:research_areas |
oncology
combination therapies with other treatments |
| gptkbp:research_focus |
gptkb:vaccine
T cell biology and engineering |
| gptkbp:revenue |
private company, revenue not publicly disclosed
|
| gptkbp:safety_features |
prioritizes patient safety in trials
favorable safety profile in trials |
| gptkbp:staff |
renowned scientists in the field
|
| gptkbp:technology |
gptkb:drug
|
| gptkbp:treatment |
aiming for improved patient outcomes
|
| gptkbp:website |
www.tessatherapeutics.com
|
| gptkbp:bfsParent |
gptkb:Ariad_Pharmaceuticals
|
| gptkbp:bfsLayer |
4
|